Table 1.
Baseline patient characteristics according to presence of NAbs >30% 1 month after 2 doses of BNT162b2 (day 50)
| Variable | <30% NAbs at day 50 (n = 57) | >30% NAbs at day 50 (n = 110) | Total (N = 167) | P |
|---|---|---|---|---|
| Age, y | 70 (66-77) | 68 (58-74) | 68 (60-75) | .03 |
| BMI, kg/m2 | 26 (24-28) | 26 (24-29) | 26 (24-29) | .47 |
| Males sex | 64.9 | 53.6 | 57.5 | .16 |
| ISS | .96 | |||
| 1 | 47.3 | 46.1 | 46.5 | |
| 2 | 27.3 | 29.4 | 28.7 | |
| 3 | 25.4 | 24.5 | 24.8 | |
| RISS | .9 | |||
| 1 | 35.9 | 32.1 | 33.3 | |
| 2 | 51.3 | 55.6 | 54.2 | |
| 3 | 12.8 | 12.4 | 12.5 | |
| Treatment category | <.001 | |||
| None | 3.5 | 8.2 | 6.6 | |
| PI based | 8.8 | 6.4 | 7.2 | |
| IMID based | 24.6 | 8.2 | 13.8 | |
| Lenalidomide maintenance | 3.5 | 19.1 | 13.8 | |
| PI plus IMID based | 8.8 | 27.2 | 21 | |
| Anti-CD38 based | 40.3 | 27.2 | 31.7 | |
| Anti-BCMA based | 10.5 | 3.6 | 6 | |
| Disease response ≥CR | 5.2 | 8.1 | 7.2 | .07 |
| Diabetes | 19.6 | 13.8 | 15.3 | .2 |
| Cardiovascular disease | 49.1 | 51.4 | 50.6 | .8 |
| Autoimmune disease | 1.8 | 2.8 | 2.4 | .8 |
| Lymphocyte count, cells per mm3 | 1200 (800-1500) | 1300 (1100-1800) | 1300 (1000-1700) | .07 |
| IgG, mg/dL | 604 (300-1145) | 965 (532-1218) | 827 (462-1213) | .01 |
| IgM, mg/dL | 19 (19-24) | 23 (19-37) | 21 (19-37) | .09 |
| IgA, mg/dL | 30 (26-125) | 93 (32-194) | 59 (28-180) | <.001 |
| NAbs at day 50, % | 20 (12-25) | 81 (59-93) | 58 (24-89) | <.001 |
| NAbs before third dose, % | 15 (7-23) | 43 (25-80) | 27 (14-66) | <.001 |
| Time from second to third dose, mo | 4.9 (4.5-5.6) | 4.9 (4.5-5.3) | 4.9 (4.5-5.4) | .4 |
Data are presented as % or median (IQR).
BMI, body mass index; CR, complete remission; Ig, immunoglobulin; IMID, immunomodulatory drug; ISS, International Staging System; PI, proteasome inhibitor; RISS, Revised International Staging System.